Tags

Type your tag names separated by a space and hit enter

Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States.
Vaccine 2012; 30(24):3717-22V

Abstract

BACKGROUND

Two rotavirus vaccines are currently approved in the United States: 3-dose RotaTeq (RV5; Merck & Co., Inc., Whitehouse Station, NJ, USA) is administered at ages 2, 4, and 6 months; and 2-dose Rotarix (RV1; GlaxoSmithKline, Research Triangle Park, NC, USA) is administered at ages 2 and 4 months. Our objective was to compare rotavirus vaccine series completion and dosing schedule compliance between cohorts of infants who received these vaccines.

METHODS

Infants aged less than 1 year who initiated a rotavirus vaccine series between 01 January 2009 and 30 June 2009 were identified in US health insurance claims data. Cohorts were formed based on vaccine brand use. Series completion and compliance with the FDA-approved and ACIP-recommended harmonized schedules were analyzed descriptively and a log binomial model was used to estimate the difference in series completion by vaccine brand while adjusting for demographic variables.

RESULTS

Among infants in the RV1 and RV5 cohorts (N=55,584), 84.3% completed a full series. A greater proportion of the RV1 cohort than the RV5 cohort completed their series (91.0% vs. 83.4%; P<0.001; multivariate-adjusted relative risk 1.07; 95% CI 1.06-1.08). In the RV1 and RV5 cohorts, respectively, 75.0% and 59.5% of infants were fully compliant with the FDA-approved administration schedule for their vaccine (P<0.001); 83.3% and 76.4% of infants were fully compliant with the harmonized schedule (P<0.001).

CONCLUSIONS

The proportion of infants that completed the series was greater and compliance with respective FDA-approved and harmonized dosing schedules was higher among infants vaccinated with RV1 than among infants who received RV5.

Authors+Show Affiliations

US Health Outcomes, Vaccines, GlaxoSmithKline, Philadelphia, PA, USA. girishanthy.x.krishnarajah@gsk.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

22214886

Citation

Krishnarajah, Girishanthy, et al. "Rotavirus Vaccine Series Completion and Adherence to Vaccination Schedules Among Infants in Managed Care in the United States." Vaccine, vol. 30, no. 24, 2012, pp. 3717-22.
Krishnarajah G, Davis EJ, Fan Y, et al. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. Vaccine. 2012;30(24):3717-22.
Krishnarajah, G., Davis, E. J., Fan, Y., Standaert, B. A., & Buikema, A. R. (2012). Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. Vaccine, 30(24), pp. 3717-22. doi:10.1016/j.vaccine.2011.12.077.
Krishnarajah G, et al. Rotavirus Vaccine Series Completion and Adherence to Vaccination Schedules Among Infants in Managed Care in the United States. Vaccine. 2012 May 21;30(24):3717-22. PubMed PMID: 22214886.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. AU - Krishnarajah,Girishanthy, AU - Davis,Elizabeth J, AU - Fan,Ying, AU - Standaert,Baudouin A, AU - Buikema,Ami R, Y1 - 2011/12/31/ PY - 2011/06/06/received PY - 2011/12/01/revised PY - 2011/12/17/accepted PY - 2012/1/5/entrez PY - 2012/1/5/pubmed PY - 2012/9/13/medline SP - 3717 EP - 22 JF - Vaccine JO - Vaccine VL - 30 IS - 24 N2 - BACKGROUND: Two rotavirus vaccines are currently approved in the United States: 3-dose RotaTeq (RV5; Merck & Co., Inc., Whitehouse Station, NJ, USA) is administered at ages 2, 4, and 6 months; and 2-dose Rotarix (RV1; GlaxoSmithKline, Research Triangle Park, NC, USA) is administered at ages 2 and 4 months. Our objective was to compare rotavirus vaccine series completion and dosing schedule compliance between cohorts of infants who received these vaccines. METHODS: Infants aged less than 1 year who initiated a rotavirus vaccine series between 01 January 2009 and 30 June 2009 were identified in US health insurance claims data. Cohorts were formed based on vaccine brand use. Series completion and compliance with the FDA-approved and ACIP-recommended harmonized schedules were analyzed descriptively and a log binomial model was used to estimate the difference in series completion by vaccine brand while adjusting for demographic variables. RESULTS: Among infants in the RV1 and RV5 cohorts (N=55,584), 84.3% completed a full series. A greater proportion of the RV1 cohort than the RV5 cohort completed their series (91.0% vs. 83.4%; P<0.001; multivariate-adjusted relative risk 1.07; 95% CI 1.06-1.08). In the RV1 and RV5 cohorts, respectively, 75.0% and 59.5% of infants were fully compliant with the FDA-approved administration schedule for their vaccine (P<0.001); 83.3% and 76.4% of infants were fully compliant with the harmonized schedule (P<0.001). CONCLUSIONS: The proportion of infants that completed the series was greater and compliance with respective FDA-approved and harmonized dosing schedules was higher among infants vaccinated with RV1 than among infants who received RV5. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22214886/Rotavirus_vaccine_series_completion_and_adherence_to_vaccination_schedules_among_infants_in_managed_care_in_the_United_States_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)02026-3 DB - PRIME DP - Unbound Medicine ER -